Table 3 Characteristics of HIV vaccination that could facilitate or hinder vaccine acceptability
From: HIV vaccine acceptability among high-risk drug users in Appalachia: a cross-sectional study
Characteristic | N(%) |
|---|---|
Price (USD) willingness to pay for a 90% effective HIV vaccine | |
$0 | 30 (6.9) |
$1 - $50 | 126 (29.1) |
$51 - $100 | 132 (30.5) |
$101 - $200 | 57 (13.2) |
$201 - $500 | 51 (11.8) |
$501 - $1000 | 28 (6.5) |
Greater than $1000 | 9 (2.1) |
Efficacy required before participant would accept an HIV vaccine (n = 423) a | |
Less than 50% | 5 (1.2) |
50% | 37 (8.7) |
60% | 5 (1.2) |
70% | 13 (3.1) |
80% | 52 (12.3) |
90% | 237 (56.0) |
100% | 74 (17.5) |
Factors that would make participant less likely to get the vaccine (n = 431) | |
Requirement for multiple doses (versus single dose) | 86 (20.0) |
Caused future HIV test results to be positive | 221 (51.3) |
Factors that would make participant more likely to get the vaccine | |
Cash incentive (n = 431) | 269 (62.4) |
Amount necessary to motivate vaccination (USD) (n = 269) | |
Less than $20 | 16 (5.9) |
$20 - $50 | 147 (54.6) |
$51 - $100 | 81 (30.1) |
$101 - $500 | 18 (6.7) |
$501 - $1000 | 4 (1.5) |
$1001 - $2000 | 2 (0.7) |
$10,000 | 1 (0.4) |
Orally administered rather than injected (n = 430) | 190 (44.2) |